LP
SMMT icon

LMR Partners’s Summit Therapeutics SMMT Stock Holding History

LMR Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
820,400
+220,000
+37% +$3.9M 0.04% 369
2026
Q1 		$11.4M Buy
600,400
+176,000
+41% +$2.85M 0.03% 374
2025
Q4 		$7.42M Buy
424,400
+15,300
+4% +$288K 0.01% 478
2025
Q3 		$8.45M Buy
409,100
+225,300
+123% +$5.46M 0.04% 376
2025
Q2 		$3.91M Buy
183,800
+47,000
+34% +$1.07M 0.03% 514
2025
Q1 		$2.64M Buy
136,800
+15,000
+12% +$301K 0.02% 596
2024
Q4 		$2.17M Buy
121,800
+21,800
+22% +$423K 0.02% 578
2024
Q3 		$2.19M Buy
100,000
+50,000
+100% +$699K 0.02% 582
2024
Q2 		$390K Buy
+50,000
New +$270K ﹤0.01% 800

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

LMR Partners's SMMT Position: Q2 2026 in Review

LMR Partners increased its Summit Therapeutics (SMMT) stake by 182% in Q2 2026, buying an estimated $1.1M and bringing the position to 96,177 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #982.

LMR Partners first reported a position in SMMT in Q1 2021 and has held it in 5 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • LMR Partners held 96,177 shares of Summit Therapeutics worth $1.4M as of Q2 2026.
  • LMR Partners bought 62,055 Summit Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Summit Therapeutics made up 0.01% of LMR Partners's portfolio in Q2 2026, its #982 holding.
  • LMR Partners first reported a position in Summit Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.